EASL 2015: Hepatitis C Treatment Effective for People with Advanced Liver Disease


New direct-acting antiviral regimens are well-tolerated and produce cure rates far exceeding those of interferon-based therapy for people with decompensated cirrhosis.

Sofosbuvir-based Therapy Effective for Hepatitis C Patients with Decompensated Cirrhosis (HCV-TARGET)

Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients (ALLY-1)

Merck Hepatitis C Combination Achieves 90% Cure in Advanced Cirrhosis Patients (C-SALT)

Sofosbuvir/Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease (SOLAR-2)